옵션 체인은 다양한 행사가격과 만기일에 대한 Johnson & Johnson의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Johnson & Johnson에 대한 시장 심리를 평가합니다..

Johnson & Johnson (NYSE:JNJ) 주식, 옵션 체인

JOHNSON & JOHNSON

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

wall street ai6

Equities

Large Cap

Macro Economic Events

Sector ETFs

Econ #s

Economics

Federal Reserve

ETFs

AMZN

FSLR

GOOGL

NVDA

ORCL

QCOM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

UBER

미국과 중국은 관세를 115%포인트 인하하여 대중국 관세를 30%로 낮춤으로써 무역전쟁을 완화하기로 합의했다.이러한 발표는 S&amp;P 500 지수가 2025년 3월 초 수준으로 회복하고 도널드 트럼프 대통령의 &#39;해방의 날&#39; 관세 충격으로 인한 손실로부터 회복하는 등 광범위한 주식 랠리를 촉발시켰다.

주간 시장 동향: 미중 무역 휴전, 트럼프의 중동 투자 유치로 증시 랠리, 유나이티드헬스 급락 등

unnamed

Biotech

Long Ideas

Opinion

Trading Ideas

ABBV

화이자(NYSE:PFE)는 10년래 최저 밸류에이션에 가까운 거래에도 불구하고, 특히 씨젠 인수를 통해 종양학 혁신을 통해 장기적인 성장을 위해 전략적으로 재편하고 있다. 시장은 여전히 코로나19 관련 매출 감소와 다가오는 특허 절벽에 집착하고 있지만, 투자자들은 회사의 극적으로 확장된 종양학 파이프라인, 탄탄한 잉여현금흐름, 2025~2026년에 상당한 주가 상승을 이끌 수 있는 여러 촉매제의 잠재력을 간과하고 있다.

화이자, 2025년에 강력하게 반등할 이유는?

President,Donald,J.,Trump,Delivers,Remarks,During,His,Visit,To

Global

Tech

AVGO

AMNZ

도널드 트럼프 대통령은 화요일(13일) 사우디아라비아의 대미 6,000억 달러 투자 약속을 발표했다. 트럼프는 이를 미국-중동 경제 협력의 &#39;황금기&#39;라고 부르며 기술, 방위, 인프라 분야의 주요 미국 기업들과 수십억 달러 규모의 거래를 잇달아 열거했다.

트럼프, 사우디로부터 6천억 달러 투자 유치···&#34;시장 더 오를 것&#34; 예측

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY&#x2122; (nipocalimab-aahu) versus other approved FcRn blockers in adults with generalized myasthenia gravis (gMG). These data, featured at the European Academy of Neurology (EAN) 2025 Congress in Helsinki, Finland, are among the 11 abstracts Johnson &amp; Johnson&nbsp;is presenting.
&nbsp;
Based on the ITC, which included the pivotal Phase 3 Vivacity-MG3 study data, IMAAVY showed comparable onset of symptom relief at Week 1 and showed consistent and sustained disease control with greater or statistically significant improvement of MG-ADLa scores versus the published Phase 3 data of other marketed FcRn blockers at several timepoints up to 24 weeksb of treatment.1 Results were consistent across multiple ITC methodsc.
<ul>
<li>Population-adjusted&nbsp;ITCs without a common control exhibited significantly greater mean improvements in MG-ADL scores favoring IMAAVY over other FcRn blockers, at Weeks 8-24d versus one comparator and at Weeks 10-14d versus another comparator.1</li>
<li>In placebo-adjusted&nbsp;ITCs, IMAAVY was associated with numerically greater efficacy versus one treatment comparator at Weeks 8e and 18-24e and versus another at Weeks 10-14e, with statistical significance at Weeks 10f and 12f</li>
</ul>

News

Johnson & Johnson Reports Data Showing IMAAVY Controls Myasthenia Gravis Symptoms Better Than Rivals

Donald Trump Jr. has joined billionaire entrepreneur Mark Cuban in publicly voicing disapproval of Sen. Elizabeth Warren (D-Mass.)&#8217;s approach to healthcare pricing.
Despite their political differences, Trump Jr. and Cuban found a common point of contention in Warren&#8217;s healthcare pricing strategy. They criticized the senator for not addressing&nbsp;the role of pharmacy benefit&nbsp;managers (PBMs) in escalating drug costs.
Warren had previously argued&nbsp;that the tax system was&nbsp;&#8220;rigged&#8221;&nbsp;because large pharmaceutical companies like&nbsp;Johnson &amp; Johnson&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) often escape federal taxes while charging exorbitant prices for their drugs. 
She wrote on X saying that the "highest drug prices in the WORLD while often paying ZERO dollars in federal taxes themselves."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Big Pharma companies like Johnson &amp; Johnson and Pfizer charge Americans the highest drug prices in the WORLD while often paying ZERO dollars in federal taxes themselves. Why? Because our tax system is rigged. Now, Republicans want to make it worse. I&#39;m fighting back. <a href="https://t.co/k7dFrXBneX">pic.twitter.com/k7dFrXBneX</a>
&mdash; Elizabeth Warren (@SenWarren) <a href="https://twitter.com/SenWarren/status/1935443373487440373?ref_src=twsrc%5Etfw">June 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban countered this by stating that PBMs, not pharmaceutical companies, are the ones controlling and manipulating drug pricing.
Also Read: <a href="https://www.benzinga.com/news/25/01/43245984/cuban-on-musk-i-have-no-problem-throwing-elon-under-the-bus-but-ill-save-it-for-when-its-truly-deser">Cuban on Musk: &#8216;I Have No Problem Throwing Elon Under the Bus, but I&#8217;ll Save It for When It&#8217;s Truly Deserved&#8217;</a>
Trump Jr. publicly supported Cuban&#8217;s viewpoint on X, despite Cuban&#8217;s well-known opposition to President Trump. This unexpected agreement highlights the growing concern over the role of PBMs in healthcare pricing.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Didn't think I'd be RTing Mark for a while, but he's 100% right on this issue. <a href="https://t.co/ofraK5IFQk">https://t.co/ofraK5IFQk</a>
&mdash; Donald Trump Jr. (@DonaldJTrumpJr) <a href="https://twitter.com/DonaldJTrumpJr/status/1935817600891601345?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
PBMs have been facing increasing scrutiny from federal regulators and lawmakers due to their influence on healthcare pricing. 
In 2020, the Federal Trade Commission released a report criticizing PBMs for imposing unfair terms on independent pharmacies, thereby favoring large corporate pharmacies like&nbsp;CVS&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).
The public criticism from Trump Jr. and Cuban underscores the growing debate over the role of PBMs in healthcare pricing. 
Warren&#8217;s focus on pharmaceutical companies, while not entirely misplaced, overlooks the significant influence of PBMs in determining drug prices.
The Federal Trade Commission&#8217;s report from last year further highlights the need for regulatory scrutiny of PBMs. As the debate continues, it remains to be seen how lawmakers will address the issue of healthcare pricing and the role of PBMs in the future.
Read Next
<a href="https://www.benzinga.com/news/politics/25/06/45829489/mark-cuban-reacts-to-elon-musk-donald-trump-feud">Mark Cuban Reacts to Elon Musk-Donald Trump Feud</a>
Image: Shutterstock/lev radin

Politics

Markets

Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing

Whales with a lot of money to spend have taken a noticeably bearish stance on Johnson &amp; Johnson.
Looking at options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $1,337,900 and 2, calls, for a total amount of $123,232.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $145.0 to $160.0 for Johnson &amp; Johnson during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Johnson &amp; Johnson options trades today is 3709.43 with a total volume of 4,332.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Johnson &amp; Johnson's big money trades within a strike price range of $145.0 to $160.0 over the last 30 days.
<h3>Johnson &amp; Johnson 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750446093_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$10.5</td>
<td>$9.85</td>
<td>$10.25</td>
<td>$160.00</td>
<td>$809.7K</td>
<td>4.0K</td>
<td>790</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$3.25</td>
<td>$3.05</td>
<td>$3.25</td>
<td>$150.00</td>
<td>$256.7K</td>
<td>6.3K</td>
<td>822</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$145.00</td>
<td>$80.5K</td>
<td>2.1K</td>
<td>90</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$10.9</td>
<td>$10.5</td>
<td>$10.9</td>
<td>$160.00</td>
<td>$73.0K</td>
<td>4.0K</td>
<td>1.1K</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.7</td>
<td>$6.55</td>
<td>$6.55</td>
<td>$155.00</td>
<td>$65.5K</td>
<td>4.1K</td>
<td>130</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
In light of the recent options history for Johnson &amp; Johnson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Trading volume stands at 4,769,606, with JNJ's price down by -0.69%, positioned at $149.69.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 26 days.</li>
</ul>
<h3>Expert Opinions on Johnson &amp; Johnson</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $181.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $181. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Johnson &amp; Johnson, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Johnson & Johnson Unusual Options Activity For June 20

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices.
What Happened: The clash, unfolding as of Friday, has reignited discussions on Pharmacy Benefit Managers (PBMs) and Big Pharma's tax practices, with the Senate poised to address reform amid rising public scrutiny.
Enter Cuban, the Dallas Mavericks owner and founder of Cost Plus Drugs, who fired back with a pointed correction.
In a post quoting Warren, Cuban argued that PBMs—not Big Pharma—are the true culprits behind inflated drug prices.
&#8220;PBMs corrupt healthcare,&#8221; he wrote, explaining that these intermediaries control formularies and manipulate prices to maximize rebate revenue, with <a href="https://www.benzinga.com/25/05/45487788/trumps-drug-price-order-hits-pbms-hardest-cvs-cigna-unh-in-focus-as-experts-highlight-racket-and-pricing-distortion">three major PBMs</a> negotiating over 90% of rebates for commercial insurance plans. 
Warren, in her post, had blamed pharmaceutical giants like Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) for charging Americans the &#8220;highest drug prices in the world&#8221; while paying &#8220;zero dollars in federal taxes.&#8221;
Citing data from her Senate Finance Committee role, Warren highlighted how these companies, alongside AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), have exploited tax loopholes from the 2017 Tax Cuts and Jobs Act to shield billions in profits.
&#8220;Republicans want to make it worse. I&#8217;m fighting back,&#8221; she declared, sharing <a href="https://www.cnbc.com/2025/06/17/pfizer-merck-jj-others-face-scrutiny-over-tax-loophole-extension.html">a</a> CNBC headline and urging action against what she calls a &#8220;rigged tax system.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No. It&#39;s because PBMs corrupt healthcare. Big Pharma wishes they could set their own pricing. They don&#39;t. PBMs control formularies and manipulate prices, in exchange for providing pharma access to patients. It&#39;s how they maximize rebate revenue. In fact, 3 PBMs NEGOTIATE… <a href="https://t.co/GpN4mnzvOM">https://t.co/GpN4mnzvOM</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1935705831930298562?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46013679/dan-ives-says-market-is-massively-underestimating-this-ai-play-urges-investors-to-look-beyong-mag-7">Dan Ives Says Market Is ‘Massively Underestimating' This AI Play, Urges Investors To Look Beyond Mag 7</a>
Why It Matters: Cuban has been a c<a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">ritic of the healthcare system</a>, saying that it should be simple. According to him, it&#8217;s become overly complicated by big insurance companies and PBMs.
These groups, he says, act as middlemen, controlling not just the costs but also the accessibility of care.
He blames PBMs for lack of transparency, inflated specialty drug prices, rebate distortion, formulary restrictions, and &#8220;Sh–ing on&#8221; on independent pharmacies.
Some significant firms engaged in the PBM business listed in the U.S. include;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>51.15%</td>
<td>9.57%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>14.54%</td>
<td>-6.95%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-39.11%</td>
<td>-36.60%</td>
</tr>
</tbody>
</table>
</figure>
Meanwhile, here is how some pharmaceutical sector ETFs have performed;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>1.69%</td>
<td>-4.48%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-0.49%</td>
<td>-1.85%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.23%</td>
<td>-1.64%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.06%</td>
<td>2.61%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>20.55%</td>
<td>22.94%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-5.44%</td>
<td>-6.27%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.49%</td>
<td>-14.63%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were mixed in premarket on Friday. The SPY was down 0.30% at $595.67, while the QQQ was 0.015% higher at $529.07, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46016347/this-stock-just-popped-30-in-5-days-now-expert-says-it-looks-potentially-explosive">This Stock Just Popped 30% In 5 Days — Now Expert Says It ‘Looks Potentially Explosive'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Insurance

AMGN

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'

Jury concludes J&amp;J concealed the danger of its asbestos-laced talcum powder that caused woman's cancer
A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) talcum powder products.
The jury found the pharmaceutical giant liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talcum powder products caused Paluzzi's terminal cancer.
During the trial, the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdobslegal.com%2F&amp;esheet=54279382&amp;newsitemid=20250618099844&amp;lan=en-US&amp;anchor=Dean+Omar+Branham+Shirley&amp;index=1&amp;md5=d9fd59b911b8494899fa30004c35d027">Dean Omar Branham Shirley</a> legal team, which represented Ms. Paluzzi, presented extensive evidence showing that Johnson &amp; Johnson had internal knowledge of asbestos in its talc supply dating back decades yet continued to market the products as safe for daily use.
J&amp;J ceased production and sale of all products containing talc in the United States in 2020. Ms. Paluzzi, a lifelong user of the company's Baby Powder on herself and her children, was diagnosed with mesothelioma in 2021.

Legal

Johnson & Johnson Found Liable In Talc Cancer Case; Jury Awards $8M To Massachusetts Resident

<a href="https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use" title="https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use">https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use</a>

General

BNTX

MRNA

NVAX

'RFK Jr. Weighs Review of Dozens of Shots, Citing Aluminum Use' - Bloomberg News

Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) short percent of float has fallen 15.79% since its last report. The company recently reported that it has 19.22 million shares sold short, which is 0.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Johnson &amp; Johnson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750183231_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson &amp; Johnson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Johnson &amp; Johnson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Johnson &amp; Johnson's peer group average for short interest as a percentage of float is 4.04%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Johnson & Johnson's Recent Short Interest

<a href="https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-u-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-pediatric-crohns-disease" title="https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-u-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-pediatric-crohns-disease">https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-u-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-pediatric-crohns-disease</a>

Johnson & Johnson seeks U.S. FDA Approval Of STELARA For The Treatment Of Pediatric Crohn's Disease; Supported By 52-Week Data From The Phase 3UNITI-Jr Study, Submission Aims To Expand STELARA Indication To Treat Children Two Years Of Age And Older

<ul>
<li>Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA</li>
<li>Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs</li>
</ul>

Reported Sunday, Johnson & Johnson's TALVEY And TECVAYLI Investigational Combination Shows 78.9% Response Rate And Deep Durability In Heavily Pretreated Multiple Myeloma With Extramedullary Disease

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease
75-80% complete response rate among evaluable patients at the recommended Phase 2 dose&nbsp;
MILAN, June 13, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not been previously treated with CAR T-cell therapy.1 Findings demonstrate the potential of JNJ-4496 in the treatment of patients with R/R LBCL, including R/R diffuse large B-cell lymphoma (DLBCL) – the most common type of aggressive lymphoma, a blood cancer that originates in the lymphatic system.1,2 These data were presented as an oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4448366-1&amp;h=2997833116&amp;u=https%3A%2F%2Fehaweb.org%2Fconnect-network%2Feha2025-congress&amp;a=2025+European+Hematology+Association+(EHA)+Congress">2025 European Hematology Association (EHA) Congress</a>&nbsp;(<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4448366-1&amp;h=3124684094&amp;u=https%3A%2F%2Flibrary.ehaweb.org%2Feha%2F2025%2Feha2025-congress%2F4159316%2Fmatthew.ku.a.global.phase.1b.study.of.jnj-90014496.a.cd19.cd20.bi-specific.html%3Ff%3Dlisting%253D0%252Abrowseby%253D8%252Asortby%253D1%252Asearch%253DJNJ-90014496&amp;a=Abstract+%23S239">Abstract #S239</a>).1
JNJ-4496, formerly known as C-CAR039, is a dual-targeting CAR T designed to bind to both CD19 and CD20 antigens — two cell surface proteins commonly expressed on malignant B-cells. This design, including a 4-1BB costimulatory domain, is intended to enhance binding strength and persistence, also potentially addressing common mechanisms of resistance in relapsed or refractory disease.
In the Phase 1b dose confirmation study (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4448366-1&amp;h=2043334395&amp;u=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT05421663%3Fintr%3DJNJ-90014496%26rank%3D1&amp;a=NCT05421663">NCT05421663</a>) in patients with R/R LBCL, data at the recommended Phase 2 dose (RP2D) were reported in patients with a median follow-up of 4 months. Results informed a RP2D of JNJ-4496 at 75 million CAR+ T-cells. Among the 22 patients in the RP2D group where efficacy was assessed, those who received one prior line of therapy (n=10) had an objective response rate (ORR) of 100 percent and a complete response rate (CRR) of 80 percent (95 percent confidence interval (CI), 69, 100). In the patients who had received two or more prior lines of therapy (n=12), the ORR was 92 percent and the CRR was 75 percent (95 percent CI, 62, 100).1

Johnson & Johnson's Dual-Targeting CD19/CD20 CAR T Therapy Phase 1b Study, Achieves 75% - 80% Complete Response Rate In Relapsed Or Refractory Large B-Cell Lymphoma Patients, Demonstrating Safety Profile At Recommended Phase 2 Dose

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new Phase 1b data showing encouraging&nbsp;antileukemic activity and a promising safety profile for bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine (VEN + AZA) for the treatment of acute myeloid leukemia (AML) harboring KMT2A gene rearrangements (KMT2Ar) or NPM1 gene mutations (NPM1m). The study evaluated patients with newly diagnosed, intensive chemo-ineligible AML and relapsed or refractory AML.1 The results were featured in an oral presentation at the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4447496-1&amp;h=3957088323&amp;u=https%3A%2F%2Fehaweb.org%2Fconnect-network%2Feha2025-congress&amp;a=2025+European+Hematology+Association+(EHA)+Congress">2025 European Hematology Association (EHA) Congress</a>&nbsp;(<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4447496-1&amp;h=3103175932&amp;u=https%3A%2F%2Flibrary.ehaweb.org%2Feha%2F2025%2Feha2025-congress%2F4159214%2Fandrew.h.wei.rp2d.determination.of.bleximenib.in.combination.with.ven2Baza.html%3Ff%3Dlisting%253D0%252Abrowseby%253D8%252Asortby%253D1%252Asearch%253Dbleximenib&amp;a=S137">S137</a>).

Johnson & Johnson Announces Bleximenib, Investigational Selective Menin Inhibitor, Shows Potential As Combination Therapy For Treatment Of Relapsed Or Refractory AML And Newly Diagnosed, Intensive Chemo-Ineligible AML

TREMFYA&nbsp;&#xAE;&nbsp;demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study
More than 40% of TREMFYA&#xAE;-treated patients across both dose groups achieved ACR50&nbsp;at Week 24
Improvement in both joint and skin symptoms reinforce TREMFYA&#xAE; as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis
BARCELONA, June 11, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced findings from the Phase 3b APEX study showing that TREMFYA&#xAE; (guselkumab) significantly reduced both signs and symptoms of active psoriatic arthritis (PsA) and inhibited progression of joint structural damage at 24 weeks compared to placebo.1 These data from a late-breaking abstract are among the 30 oral and poster presentations Johnson &amp; Johnson is highlighting at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress.
In the Phase 3b APEX study, TREMFYA&#xAE; significantly inhibited progression of joint structural damage, including joint erosions and space narrowing, in patients with active PsA at Week 24 as assessed by the PsA modified van der Heijde-Sharp (vdH-S) score. The mean change from baseline to Week 24 in the modified van der Heijde-Sharp (vdH-S) score was 0.55 and 0.54 for patients receiving TREMFYA&#xAE; every four weeks (Q4W) and every eight weeks (Q8W) respectively, compared with 1.35 in the placebo group (p=0.002 for Q4W and p&lt;0.001 for Q8W dosing versus placebo, respectively). In the two TREMFYA&#xAE; dose groups, 67% (Q4W) and 63% (Q8W) of patients experienced no radiographic progression, versus 53% in the placebo group.a,1

Johnson & Johnson's TREMFYA Reduces Joint Damage And Improves Psoriatic Arthritis Symptoms In Phase 3b APEX Study, With Over 40% Achieving ACR50 And Majority Showing No Radiographic Progression At 24 Weeks

June 6, 2025 records indicate that Representative Gilbert Ray Cisneros filed a purchase of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), valued between $39,025 and $410,000. According to the June filing, the transaction occurred on May 30, 2025.
Currently, Johnson &amp; Johnson shares are trading down 0.19% at $154.74.
<h3>Representative's Recent Trading Activity</h3>
In the last three years, Gilbert Ray Cisneros completed 222 stock transactions totaling more than $2.45 million. Hawaiian Electric Indus and Aris Water Solutions stocks were among the largest trades. Some of the most notable transactions the Rep. has executed recently include: 
<ul>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>): $15,001 - $50,000 Purchase</li>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>): $1,001 - $15,000 Sale</li>
<li>Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): $1,001 - $15,000 Purchase</li>
</ul>
Here's a summary of Gilbert Ray Cisneros's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centene</td>
<td>CNC</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-05-30</td>
</tr>
<tr>
<td>Boeing</td>
<td>BA</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-05-30</td>
</tr>
<tr>
<td>Conagra Brands</td>
<td>CAG</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-05-30</td>
</tr>
<tr>
<td>ConocoPhillips</td>
<td>COP</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S (Partial)</td>
<td>2025-05-30</td>
</tr>
<tr>
<td>Elevance Health</td>
<td>ELV</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-05-30</td>
</tr>
</tbody>
</table>
To stay updated on Gilbert Ray Cisneros's trades and other congressional trades, try our <a href="https://www.benzinga.com/gov-trades/members/gilbert-ray-cisneros">government trades tool</a> for live updates!
<h3>Why Congressional Transactions Matter</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Rep. Gilbert Ray Cisneros Has Bought Up to $410K Worth Of Johnson & Johnson Stock: Here's What You Should Know

Analysts' ratings for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.33, with a high estimate of $181.00 and a low estimate of $153.00. This current average has decreased by 0.44% from the previous average price target of $170.08. 
<img src="https://www.benzinga.com/files/images/story/2025/1749150069_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Johnson &amp; Johnson. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$153.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$164.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$169.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$159.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$164.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Asad Haider</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$172.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Johnson &amp; Johnson. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Johnson &amp; Johnson compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Johnson &amp; Johnson's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Johnson &amp; Johnson's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JNJ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Johnson &amp; Johnson analyst ratings.</a>
<h2>Unveiling the Story Behind Johnson &amp; Johnson</h2>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<h3>Johnson &amp; Johnson's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Johnson &amp; Johnson's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 2.39%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Johnson &amp; Johnson's net margin is impressive, surpassing industry averages. With a net margin of 50.24%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Johnson &amp; Johnson's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 14.7%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Johnson &amp; Johnson's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.89% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Johnson &amp; Johnson's debt-to-equity ratio is below the industry average. With a ratio of 0.67, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

12 Analysts Have This To Say About Johnson & Johnson

Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) on Thursday collaborated with Dr. Reddy's Laboratories Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45788813/alvotech-and-dr-reddys-enter-into-collaboration-to-co-develop-biosimilar-candidate-to-keytruda-pem" rel="noreferrer noopener">for global markets</a>.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) is indicated for numerous cancer types.
Keytruda's worldwide sales were $29.5 billion in 2024. The collaboration combines Dr. Reddy's and Alvotech's capabilities in biosimilars, speeding up the development process and extending the global reach for this biosimilar candidate.
Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
Subject to certain exceptions, each party will have the right to commercialize the product globally.
In May, the U.S. Food and Drug Administration (FDA) approved&nbsp;Teva and&nbsp;Alvotech Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic&nbsp;Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45199025/why-is-israel-based-generic-drug-focused-teva-pharmaceutical-stock-trading-higher-on-monday" rel="noreferrer noopener">Stelara (ustekinumab)</a>.
In March, Alvotech&nbsp;announced the acquisition of&nbsp;R&amp;D operations of&nbsp;Xbrane Biopharma AB along with a biosimilar candidate, XB003, which is based on Cimzia (certolizumab pegol)&nbsp;for <a target="_blank" href="https://www.benzinga.com/news/mid-cap/25/03/44412592/alvotech-strengthens-biosimilar-portfolio-with-27-million-xbrane-rd-deal" rel="noreferrer noopener">around SEK275 million</a> (around $27 million).
The transaction includes a cash payment of SEK102.2 million at closing, along with the assumption of SEK172.8 million in debt and accounts payable.
HSBC upgraded Dr Reddy's Laboratories from Hold to Buy and raised the price <a target="_blank" href="https://www.benzinga.com/quote/RDY/analyst-ratings" rel="noreferrer noopener">forecast from $14.44 to $16.9</a>.
<h2 class="wp-block-heading">Stock Prediction For 2025 For Alvotech</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Alvotech, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Alvotech, the 200-day moving average sits at $11.44, according to <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">Benzinga Pro</a>, which is above the current price of $10.46. For more on charts and trend lines, <a target="_blank" href="https://pro.benzinga.com/" rel="noreferrer noopener">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: At the last check on Thursday, RDY stock was up 6.07% at $15.65, and ALVO stock was down 2.49% at $10.56.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/biotech/25/06/45799258/gileads-hiv-pipeline-gains-traction-with-upcoming-fda-decision-for-hiv-1-drug" target="_blank" rel="noreferrer noopener">Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Health Care

Contracts

Movers

ALVO

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

RBC Capital analyst Shagun Singh reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and maintains $181 price target.

Price Target

Reiteration

RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $181 Price Target

AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rheumatoid arthritis</a>.
In the 424-patient 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45757627/anaptys-announces-positive-rosnilimab-data-updated-through-six-months-in-robust-phase-2b-trial-in-" rel="noreferrer noopener">over six months</a>.
Furthermore, responses were then durable for at least two months off the drug.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42445688/anaptysbio-discontinues-investment-in-eczema-candidate-after-disappointing-data" rel="noreferrer noopener">AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data</a>
Rosnilimab was safe and well tolerated, particularly compared to standard-of-care biologics or JAKs.
All three doses (100mg Q4W, 400mg Q4W, 600mg Q2W) achieved statistically significant reductions in DAS-28 CRP and ACR20 at Week 12 versus placebo.
CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses by Week 14.
The company aims to complete its Phase 2 study for rosnilimab in ulcerative colitis/UC, with initial data expected in the fourth quarter of 2025.
As of the March 11, 2025&nbsp;data cutoff date, 83% were still in LDA at Week 34 across all doses. Of the remaining 17% of patients who did not sustain CDAI LDA at Week 34, most remained near the cutoff of CDAI=10, with a median CDAI of 13.
Rosnilimab demonstrated clinically meaningful improvements that deepened through Week 28 across multiple validated patient-reported outcomes, including the pain visual analog scale (VAS) and the health assessment questionnaire, or HAQ-Disability Index (DI), a self-reporting tool to measure function and disability.
HC Wainwright analyst Emily Bodnar wrote on Wednesday, &#8220;Given the data showcase a positive holistic story for rosnilimab in RA, we are increasingly positive on upcoming UC data.&#8221;
Bodnar upgraded AnaptysBio from Neutral to Buy, raising the price target<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings" target="_blank" rel="noreferrer noopener"> from $22 to $38</a>.
HC Wainwright Highlights Competitor Datasets
Data using non-responder imputation (NRI) from Week 24 of the SELECT-CHOICE trial, which compared AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Rinvoq vs Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Orencia in rheumatoid arthritis (RA), showed similar results for both drugs. These findings align with the results seen for the company&#8217;s rosnilimab at Week 28, even though about 29% of patients had previously been treated with JAK inhibitors.
In contrast, Eli Lilly And Co&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) now-discontinued PD-1 agonist peresolimab showed a drop in CDAI LDA rates—from 55% at Week 14 to 37% at Week 24. This is notably lower than the 53–63% range reported for rosnilimab at Week 28.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is also set to present early data for its PD-1 agonist at the upcoming EULAR conference, though its study is smaller than AnaptysBio&#8217;s.
Price Action: ANAB stock is down 12.1% at $20.66 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45769045/tariffs-ai-and-trade-war-apples-smartphone-growth-to-take-a-hit-experts-say" target="_blank" rel="noreferrer noopener">Tariffs, AI And Trade War: Apple&#8217;s Smartphone Growth To Take A Hit, Experts Say</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Upgrades

ANAB

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) shared data from several <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">cancer studies</a> at the 2025 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday.
Here&#8217;s that the New Brunswick, New Jersey-based company released.
<h3 class="wp-block-heading">Phase 3 AMPLITUDE Study</h3>
Johnson &amp; Johnson released promising Phase 3 results from the AMPLITUDE study evaluating niraparib combined with abiraterone acetate plus prednisone (AAP) in metastatic castration-sensitive prostate cancer (mCSPC) patients with homologous recombination repair (HRR) genetic alterations, including BRCA mutations.
Key findings:
<ul class="wp-block-list">
<li>The study met its primary endpoint of radiographic progression-free survival (rPFS) among 696 patients.</li>
<li>Patients with BRCA mutations (n=191) saw the strongest benefit: 
<ul class="wp-block-list">
<li>Median rPFS was not reached vs. 26 months for placebo group</li>
<li>48% reduced risk of radiographic progression or death</li>
</ul>
</li>
<li>All HRR-altered patients also benefited: 
<ul class="wp-block-list">
<li>Median rPFS not reached vs. 29.5 months for placebo</li>
<li>37% reduced risk of progression or death</li>
</ul>
</li>
<li>Symptomatic progression was significantly reduced: 
<ul class="wp-block-list">
<li>56% reduction in BRCA patients</li>
<li>50% reduction in HRR patients</li>
</ul>
</li>
<li>Early overall survival (OS) data shows a positive trend: 
<ul class="wp-block-list">
<li>25% reduced risk of death in BRCA patients</li>
<li>21% reduction in HRR patients</li>
<li>OS data still maturing</li>
</ul>
</li>
</ul>
In summary, the combination therapy significantly delays disease progression and shows encouraging early signs of extending survival in genetically selected mCSPC patients.
<h3 class="wp-block-heading">JNJ-79635322 Phase 1 Study</h3>
Johnson &amp; Johnson released initial Phase 1 results of JNJ-79635322 for relapsed or refractory multiple myeloma.
The overall response rate (ORR) among the 36 patients who received the recommended phase 2 dose (RP2D) was 86.1%. In the 27 patients who were naive to BCMA and GPRC5D-directed therapies, the ORR <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45749276/early-results-from-johnson-johnsons-trispecific-antibody-show-promising-response-in-heavily-pretre" rel="noreferrer noopener">was 100% at the RP2D</a>.
<h3 class="wp-block-heading">Phase&nbsp;1b/2 CARTITUDE-1 Study</h3>
The company&nbsp;also revealed new long-term follow-up data from the Phase&nbsp;1b/2 CARTITUDE-1 study demonstrating 33% (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI&nbsp;(ciltacabtagene autoleucel; cilta-cel) achieved PFS of five years or more with a single infusion and no maintenance or subsequent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45749277/single-infusion-of-carvykti-ciltacabtagene-autoleucel-delivered-lasting-treatment-free-remissions-" rel="noreferrer noopener">anti-myeloma therapy</a>.
A subset of 12 patients who underwent serial evaluations at a single site remained minimal residual disease (MRD) negative and imaging negative throughout five years of post-treatment follow-up.
At a median follow-up of 61.3 months, the median OS was 60.7 months.
With longer follow-up, the safety profile in CARTITUDE-1 was consistent with the known safety profile of CARVYKTI, with no new safety signals observed.
There were two newly reported second primary malignancies (both solid tumors) and no new Parkinsonism events or cranial nerve palsies.
<h3 class="wp-block-heading">Phase 3 PERSEUS and Phase 3 CEPHEUS Studies</h3>
Johnson &amp; Johnson&nbsp;highlighted data from two studies of DARZALEX&nbsp;FASPRO (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained MRD negativity rates and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45749281/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-regimen-shows-95-percent-progression-free" rel="noreferrer noopener">regardless of transplant status</a>.
<h3 class="wp-block-heading">Phase 3 PERSEUS Study</h3>
New analysis from the Phase 3 PERSEUS study shows the addition of DARZALEX&nbsp;FASPRO to bortezomib, lenalidomide and dexamethasone (D-VRd), followed by an investigational maintenance regimen of DARZALEX&nbsp;FASPRO with lenalidomide (D-R), led to improved and deepened rates of overall and sustained MRD negativity, defined as no cancer cells detected within 100,000 bone marrow cells for at least 24 months, compared to VRd induction and consolidation with R maintenance.
More than half of patients who received the DARZALEX&nbsp;FASPRO-based regimen achieved sustained MRD negativity for 24 or more months, and more than two-thirds of patients achieved sustained MRD negativity at 12 months, showing 95.3% PFS at 48 months.
<h3 class="wp-block-heading">Phase 3 CEPHEUS Study</h3>
The post-hoc analysis of the Phase 3 CEPHEUS study focused exclusively on transplant-ineligible patients, showing that DARZALEX&nbsp;FASPROto VRd significantly deepens response and prolongs PFS compared to VRd alone.
Data from the Phase 3 CEPHEUS study show 60% overall MRD negativity and improved PFS with DARZALEX FASPRO&nbsp;in transplant-ineligible newly diagnosed patients.
Price Action: JNJ stock is down 0.62% at $154.40 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45745671/ferguson-stock-soars-on-strong-q3-growth-margin-gains-and-upbeat-guidance" target="_blank" rel="noreferrer noopener">Ferguson Stock Soars On Strong Q3 Growth, Margin Gains And Upbeat Guidance</a></li>
</ul>
Image: Shutterstock

Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI&#xAE;&nbsp;remain progression-free
CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment
CHICAGO, June 3, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI&#xAE; (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These data underscore Johnson &amp; Johnson's dedication to advancing transformative therapies that aim to reshape the treatment landscape for patients with multiple myeloma.
In a subset of 12 patients who underwent serial evaluations at a single site, all were minimal residual disease (MRD) negative and imaging negative throughout five years of post-treatment follow-up. Findings were featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7507). The data were also simultaneously published in The Journal of Clinical Oncology.

Johnson & Johnson Says New Long-Term CARTITUDE-1 Data Show One-Third Of Patients Treated With CARVYKTI Remain Progression-Free

More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO&#xAE;&nbsp;for 24 months or longer in the Phase 3 PERSEUS study
Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO&#xAE; in transplant-ineligible newly diagnosed patients
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced data from two studies highlighting that a DARZALEX FASPRO&#xAE; (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2,3 Findings were highlighted as oral presentations of an analysis of sustained MRD in transplant-eligible patients from the Phase 3 PERSEUS study (Abstract #7501) and a subgroup analysis of transplant-ineligible patients in the Phase 3 CEPHEUS study (Abstract #7516) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Johnson & Johnson Announces Data From Two Studies Highlighting That DARZALEX FASPRO-Based Quadruplet Regimen Demonstrated Deep And Sustained MRD Negativity Rates, And Improved Long-Term PFS In NDMM Patients

Press Releases

Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

RBC Capital

Leerink Partners

Barclays

Raymond James

Morgan Stanley

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Johnson & Johnson

Johnson & Johnson (JNJ) 옵션

Johnson & Johnson (NYSE:JNJ) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌